US · Healthcare

RVL Pharmaceuticals plc (RVLPQ)

Biotechnology

RVL Pharmaceuticals plc (RVLPQ) is listed on US in the Healthcare sector. Industry: Biotechnology. As of 2026-05-23, reported P/E ratio is 25.00. Use this page for a quick overview, then open the MyAverix Finance app for income statements, balance sheet, cash flow, and news.

Download on the App Store Get it on Google Play

Key metrics for RVLPQ

P/E ratio

25.00

RVL Pharmaceuticals plc (RVLPQ) — FAQ

What is RVLPQ's P/E ratio?

The price-to-earnings (P/E) ratio for RVL Pharmaceuticals plc (RVLPQ) is 25.00 (data as of 2026-05-23).

Does RVL Pharmaceuticals plc pay a dividend?

Dividend yield is not available in the current snapshot for RVL Pharmaceuticals plc (RVLPQ). Check the MyAverix Finance app for the latest dividend data.

What sector is RVL Pharmaceuticals plc in?

RVL Pharmaceuticals plc (RVLPQ) is classified in the Healthcare sector (Biotechnology industry).

What exchange is RVLPQ listed on?

RVLPQ is listed on US.

Full report in the app

Get the full report in the MyAverix Finance app — income, balance sheet, cash flow, ratios, and multi-year trends in one place.

Related Healthcare companies

Abbott Laboratories (ABT) AbbVie Inc. CDR (ABBV) Agilent Technologies Inc. (A1GI34) Aimed Bio (0009K0) Alnylam Pharmaceuticals, Inc. (A1LN34) Alvotech (ALVO) Amgen Inc (AMGN34) argenx SE (A1RG34)